Determination of the maximal carcinoma/normal skin ratio after HpD or m-THPC administration in Hairless mice (SKH-1) by fluorescence spectroscopy.

abstract：:Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer. Pegylated liposomal doxorubicin (Caelyx) has been combined with this regimen in a phase I study exhibiting promising activity in patients with upper gastrointestinal tumors...

journal_title：Anti-cancer drugs

authors： Gnad-Vogt SU,Hofheinz RD,Saussele S,Kreil S,Willer A,Willeke F,Pilz L,Hehlmann R,Hochhaus A

更新日期：2005-04-01 00:00:00

abstract：:beta-Lapachone is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae) with cancer chemopreventive properties. The objective of the present study was to investigate the effect of beta-lapachone on the cell growth and apoptosis in human colon carcinoma tumor cell line HCT-116....

journal_title：Anti-cancer drugs

authors： Choi BT,Cheong J,Choi YH

更新日期：2003-11-01 00:00:00

abstract：:The immunotherapy significantly improved survival of non-small cell lung cancer patients, but it may cause immune-related adverse events, which are severe in less than 10% of cases. We report the case of one patient who developed myositis and myasthenia during nivolumab treatment for metastatic lung squamous carcinoma...

journal_title：Anti-cancer drugs

authors： Veccia A,Kinspergher S,Grego E,Peterlana D,Berti A,Tranquillini E,Caffo O

更新日期：2020-06-01 00:00:00

abstract：:This study aims to explore the effect and mechanism of pyruvate kinase M2 (PKM2) on chemotherapy resistance of estrogen receptor-positive breast cancer (ER BC) by regulating aerobic glycolysis. The expression of PKM2 in ER BC MCF-7 cells, T47D cells and MCF-7/ADR cells (which are subject to adriamycin/ADR induction) w...

journal_title：Anti-cancer drugs

authors： Qian Y,Bi L,Yang Y,Wang D

更新日期：2018-08-01 00:00:00

abstract：:Preoperative chemoradiotherapy (CRT) is generally performed for locally advanced rectal cancer (LARC, cStage 2 or 3) to improve local disease control and patient survival. The pathological tumor response to CRT is a surrogate marker that is associated with oncological outcome. Thus, markers that predict the response t...

journal_title：Anti-cancer drugs

authors： Roh K,Yeo SG,Yoo BC,Kim KH,Kim SY,Kim MJ

更新日期：2016-09-01 00:00:00

abstract：:9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

journal_title：Anti-cancer drugs

authors： Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

更新日期：1998-01-01 00:00:00

abstract：:We report Guillain-Barre syndrome (GBS), developed in a patient with metastatic colon cancer, receiving oxaliplatin-based chemotherapy. The 53-year-old patient was treated with first-line chemotherapy consisting of oxaliplatin 45 mg/m2, 5-fluorouracil 450 mg/m2 and folinic acid 200 mg/m2, all given on the same day in ...

journal_title：Anti-cancer drugs

authors： Christodoulou C,Anastasopoulos D,Visvikis A,Mellou S,Detsi I,Tsiakalos G,Pateli A,Klouvas G,Papadimitriou A,Skarlos DV

更新日期：2004-11-01 00:00:00

abstract：:This review focuses on the recent advances in chemotherapy of malignant gliomas, with special emphasis on the most common primary brain tumor in adults, glioblastoma. The demonstration of the superiority of concomitant and adjuvant temozolomide with standard radiotherapy over radiotherapy alone in patients with newly ...

journal_title：Anti-cancer drugs

authors： Soffietti R,Rudà R,Trevisan E

更新日期：2007-07-01 00:00:00

abstract：:The current reference treatment of hormone-refractory prostate cancer consists mainly of chemotherapy with docetaxel. To improve the management of advanced prostate cancer, one should examine the benefits of adding other agents to docetaxel. We examined the growth inhibitory effects of a triple combination, including ...

journal_title：Anti-cancer drugs

authors： Fischel JL,Ciccolini J,Formento P,Ferrero JM,Milano G

更新日期：2006-08-01 00:00:00

abstract：:The camptothecin derivative 9-nitrocamptothecin (9-NC) has demonstrated clinical activity in patients with ovarian and pancreatic carcinomas. Preclinical studies have shown promising activity of 9-NC for melanoma. We have thus conducted a phase II clinical trial of 9-NC for patients with metastatic cutaneous and uveal...

journal_title：Anti-cancer drugs

authors： Ellerhorst JA,Bedikian AY,Smith TM,Papadopoulos NE,Plager C,Eton O

更新日期：2002-02-01 00:00:00

abstract：:Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old wom...

journal_title：Anti-cancer drugs

authors： Hirashima Y,Kobayashi H,Nishiguchi T,Miura K,Kanayama N

更新日期：2001-08-01 00:00:00

abstract：:A combined treatment with conventional chemotherapies can enhance the effectiveness of chemotherapeutic agents against cancers. Here, we have shown that the naturally occurring triterpenoids synergistically enhance the response of cervical cancer cells to taxol. Of the triterpenoid compounds, pristimerin enhanced the ...

journal_title：Anti-cancer drugs

authors： Eum DY,Byun JY,Yoon CH,Seo WD,Park KH,Lee JH,Chung HY,An S,Suh Y,Kim MJ,Lee SJ

更新日期：2011-09-01 00:00:00

abstract：:This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21,...

journal_title：Anti-cancer drugs

authors： van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

更新日期：1999-04-01 00:00:00

abstract：:Apoptosis is important for normal development and removal of damaged cells. Evasion of apoptosis by cancer cells is one of the key characteristics of many tumor types. Thus, discovering agents that promote apoptosis in tumor cells could have great therapeutic value. Marine natural products have demonstrated great pote...

journal_title：Anti-cancer drugs

authors： LaBarbera DV,Modzelewska K,Glazar AI,Gray PD,Kaur M,Liu T,Grossman D,Harper MK,Kuwada SK,Moghal N,Ireland CM

更新日期：2009-07-01 00:00:00

abstract：:Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

journal_title：Anti-cancer drugs

authors： Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

更新日期：2018-09-01 00:00:00

abstract：:The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in t...

journal_title：Anti-cancer drugs

authors： Du J,Hu C,Zhang Y,Hu B,Wang F,Zhang Y

更新日期：2015-01-01 00:00:00

abstract：:The efficacy of chemotherapy for advanced gastric cancer with palliative intent compared with supportive care alone is now widely accepted. However, the best choice of chemotherapy regimen for patients with advanced gastric cancer is still a matter of controversy and requires further investigation. This study is perfo...

journal_title：Anti-cancer drugs

authors： Cao W,Yang W,Lou G,Jiang J,Geng M,Xi W,Li H,Ma T,Jin Y

更新日期：2009-04-01 00:00:00

abstract：:Docetaxel (DTX) is one of the most effective antineoplastic drugs. However, its current clinical administration, formulated in tween80, causes serious side effects. This study is focused on preparation and evaluation of poly(lactide-co-glycolide) nanoparticles (NPs) containing DTX to remove tween80. Drug encapsulation...

journal_title：Anti-cancer drugs

authors： Esmaeili F,Dinarvand R,Ghahremani MH,Ostad SN,Esmaily H,Atyabi F

更新日期：2010-01-01 00:00:00

abstract：:Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As...

journal_title：Anti-cancer drugs

authors： de Kraker J

更新日期：1991-08-01 00:00:00

abstract：:Our previous studies have demonstrated the in-vitro and in-vivo targeting of a generation-5 (G5) dendrimer-based multifunctional conjugate, which used folic acid (FA) as the targeting agent and methotrexate (MTX) as the chemotherapeutic drug. For the synthesized G5-FA-MTX nanodevice conjugate to be clinically applicab...

journal_title：Anti-cancer drugs

authors： Myc A,Douce TB,Ahuja N,Kotlyar A,Kukowska-Latallo J,Thomas TP,Baker JR Jr

更新日期：2008-02-01 00:00:00

abstract：:Methoxymorpholinyl doxorubicin (PNU 152243) is a morpholinyl analog possessing a methoxymorpholinyl group at the 3' position of the sugar moiety, which, compared with doxorubicin, appears to be less cardiotoxic and more cytotoxic against multidrug-resistant tumor cells. In this study, we report the anticancer activity...

journal_title：Anti-cancer drugs

authors： Yuan S,Zhang X,Lu L,Xu C,Yang W,Ding J

更新日期：2004-07-01 00:00:00

abstract：UNLABELLED:Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performa...

journal_title：Anti-cancer drugs

authors： Kudelka AP,Winn R,Edwards CL,Downey G,Greenberg H,Dakhil SR,Freedman RS,LoCoco S,Umbreit J,Delmore JE,Arbuck S,Loyer E,Gacrama P,Fueger R,Kavanagh JJ

更新日期：1997-08-01 00:00:00

abstract：:Temozolomide (TMZ) combination with whole-brain radiotherapy (WBRT) has been tested by many randomized controlled trials in the treatment of brain metastases (BMs) in China and other countries. We performed an up-to-date meta-analysis to determine (i) the log odds ratios (LORs) of objective response (ORR) and adverse ...

journal_title：Anti-cancer drugs

authors： Bai GR,An JB,Chu Y,Wang XY,Li SM,Yan KJ,Lü FR,Gu N,Griffin AN,Sun BY,Li W,Wang GC,Zhou SP,Sun H,Liu CX

更新日期：2016-01-01 00:00:00

abstract：:Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Maltezos E

更新日期：2006-02-01 00:00:00

abstract：:In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

journal_title：Anti-cancer drugs

authors： Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

更新日期：2003-02-01 00:00:00

abstract：:The standard-of-care for advanced small cell lung cancer (SCLC) is chemotherapy with cisplatin+etoposide (C+E). Most patients have chemosensitive disease at the outset, but disease frequently relapses and limits survival. Efforts to improve therapeutic outcomes in SCLC and other neuroendocrine cancers have focused on ...

journal_title：Anti-cancer drugs

authors： Balasubramaniam S,Redon CE,Peer CJ,Bryla C,Lee MJ,Trepel JB,Tomita Y,Rajan A,Giaccone G,Bonner WM,Figg WD,Fojo T,Piekarz RL,Bates SE

更新日期：2018-06-01 00:00:00

abstract：:The presence of DNA fragments circulating in cancer patients was described a number of years ago. The mere presence of DNA in the circulation is not indicative of cancer. However, there are reports that apoptosis and necrosis of the cancer cells can increase the levels of circulating DNA. The study of plasma DNA with ...

journal_title：Anti-cancer drugs

authors： Shao ZM,Nguyen M

更新日期：2002-04-01 00:00:00

abstract：:Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer. The synergism of these drugs has been demonstrated in vivo and in vitro. The aim of this study was to determine the recommended dose of the triple combination of L-OHP, CPT-11 and CI 5-FU for a...

journal_title：Anti-cancer drugs

authors： Abad A,Massutí B,Gallego J,Yuste AL,Manzano JL,Carrato A,Antón A,Marfa X,Diaz-Rubio E,Spanish Cooperative Group for Gastrointestinal Tumor Therapy.

更新日期：2004-06-01 00:00:00

abstract：:The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7 resistant to adria...

journal_title：Anti-cancer drugs

authors： Chen Q,Meng YQ,Xu XF,Gu J

更新日期：2017-09-01 00:00:00

abstract：:DNA has been one of the major targets of cancer chemotherapy. A variety of anti-neoplastic agents can cause different types of DNA lesions, including base alterations, single- or double-strand DNA breaks, DNA-DNA cross-links and DNA-protein cross-links. The exact processes by which these DNA lesions lead to cell death...

journal_title：Anti-cancer drugs

authors： Kubota M

更新日期：1991-12-01 00:00:00